Prognostic Biomarkers Market Size & Share, by Indication (Oncology, Cardiological Disease, Diabetes); End-user (Hospitals, Diagnosis Centers, Research Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3091
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Prognostic Biomarkers Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2025-2037.
 

The growth of the market can be attributed to the recurrence of chronic diseases, even after complete treatment. Diseases, such as, cancer, depression, hepatitis B and C, eczema, and autoimmune diseases tend to come back, despite successful treatment, due to genetic structure of patients, or other factors. The recurrence rate of cancer varies from type to type, with breast, bladder, and leukemia cancer having 20-30% chances of recurrence, while ovarian cancer and glioblastoma have 85-90% recurrence rate. Prognostic biomarkers are used to study likely patient health outcome, which is estimated to drive the growth of the market. Moreover, increasing medical research and advancement, along with expanding personal disposable income and health awareness among people is estimated to boost the prognostic biomarkers market growth.  


Get more information on this report: Request Free Sample PDF

Prognostic Biomarkers Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Cases of Disease Recurrence
  • Growing Health Awareness Among People

Challenges

  • Unavailability of Proper Advanced Technology in Developing Nations
  • High Cost of Prognostics Biomarkers

Prognostic Biomarkers Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

#N/A

Base Year Market Size (2024)

#N/A

Forecast Year Market Size (2037)

#N/A

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Prognostic Biomarkers Segmentation

The prognostic biomarkers market is segmented by indication into oncology, cardiological diseases, diabetes, and others, out of which, the oncology segment is anticipated to hold the largest share in the market during the forecast period on account of high rate of recurrence of cancer, along with increasing prevalence of cancer. According to a report by the World Health Organization (WHO), cancer is the second leading cause of death, causing one out of every six deaths globally. In the year 2020, more than 10 million deaths were caused by cancer. In other report WHO stated that 30% to 50% of the cancer cases can be prevented by avoiding risk factors and early diagnosis.

Our in-depth analysis of the global market includes the following segments:

           Indication

  • Oncology
  • Cardiological Disease
  • Diabetes
  • Others

             End-User

  • Hospital
  • Diagnosis Centers
  • Research Institutes
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Prognostic Biomarkers Industry - Regional Synopsis

Regionally, the prognostic biomarkers market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America industry is predicted to account for largest revenue share by 2037, on the back of increasing health awareness among people, along with high per capita healthcare expenditure by the government. According to other report of the WHO, per capita healthcare expenditure in North America valued around USD 10,050.279 in the year 2018.

The market in the Europe region is estimated to witness highest CAGR over the forecast period owing to the high prevalence of cancer, and other chronic disease, backed by the growing geriatric population and advancing medical facilities.

The market in the Asia Pacific is also projected to record notable growth over the forecast period, owing to the increasing incidences of diseases, such as, diabetes, and hypertension among the exponentially growing population with over 65% of the population in the region suffering from diabetes, backed by the changing lifestyle in the region. Moreover, growing healthcare sector, along with the economic growth in the region, is estimated to boost the prognostic biomarkers market growth.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Prognostic Biomarkers Landscape

    • Meso Scale Diagnostics, LLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PerkinElmer Inc.
    • Myriad Genetics, Inc.
    • Siemens Healthcare GmbH
    • F. Hoffmann-La Roche Ltd
    • Epigenomics AG
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • QIAGEN GmbH
    • Biomarker Technologies, Inc.

Author Credits:  Radhika Pawar


  • Report ID: 3091
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Prognostic Biomarkers Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2025-2037.

Rising cases of chronic disease recurrence will impel the market growth.

North America industry is predicted to account for largest revenue share by 2037, on the back of increasing health awareness among people, along with high per capita healthcare expenditure by the government.

The major players in the market are PerkinElmer Inc., Myriad Genetics, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., and others.
Prognostic Biomarkers Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample